The Claim
In patients with early-stage Alzheimer’s disease who receive weekly 7 mg rapamycin, the 48-hour post-dose blood concentration exhibits the lowest interindividual variability (coefficient of variation = 0.28) and the strongest correlation with pre-dose trough levels (r = 0.72), indicating it is the optimal time point for pharmacokinetic monitoring in future clinical studies.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with early Alzheimer’s taking a weekly 7 mg rapamycin pill, checking their blood 48 hours after the dose gives the most consistent results and best predicts their baseline levels—so that’s the best time to test it.
See the scientific wording
In patients with early-stage Alzheimer’s disease receiving weekly 7 mg rapamycin, the 48-hour post-dose blood concentration shows the lowest interindividual variability (coefficient of variation = 0.28) and strongest correlation with pre-dose trough levels (r = 0.72), making it the optimal time point for pharmacokinetic monitoring in future studies.
What the research says
1 studyStudy: Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease
The study tested the same rapamycin treatment in Alzheimer’s patients and found that checking blood levels 48 hours after the dose gives the most consistent and predictable results, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.